You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Resveratrol abrogates the Temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the Temozolomide-induced senescence in glioma cells
|
|---|---|
| Published in |
BMC Cancer, March 2013
|
| DOI | 10.1186/1471-2407-13-147 |
| Pubmed ID | |
| Authors |
Eduardo C Filippi-Chiela, Marcos Paulo Thomé, Mardja Manssur Bueno e Silva, Alessandra Luíza Pelegrini, Pitia Flores Ledur, Bernardo Garicochea, Lauren L Zamin, Guido Lenz |
| Abstract |
Temozolomide (TMZ) is the most widely used drug to treat glioblastoma (GBM), which is the most common and aggressive primary tumor of the Central Nervous System and one of the hardest challenges in oncotherapy. TMZ is an alkylating agent that induces autophagy, apoptosis and senescence in GBM cells. However, therapy with TMZ increases survival after diagnosis only from 12 to 14.4 months, making the development of combined therapies to treat GBM fundamental. One candidate for GBM therapy is Resveratrol (Rsv), which has additive toxicity with TMZ in several glioma cells in vitro and in vivo. However, the mechanism of Rsv and TMZ additive toxicity, which is the aim of the present work, is not clear, especially concerning cell cycle dynamics and long term effects. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 22% |
| Spain | 1 | 11% |
| Brazil | 1 | 11% |
| New Zealand | 1 | 11% |
| Trinidad and Tobago | 1 | 11% |
| Unknown | 3 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 8 | 89% |
| Scientists | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 92 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Sweden | 1 | 1% |
| Canada | 1 | 1% |
| Brazil | 1 | 1% |
| Unknown | 89 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 24 | 26% |
| Student > Master | 14 | 15% |
| Student > Bachelor | 10 | 11% |
| Researcher | 6 | 7% |
| Student > Doctoral Student | 4 | 4% |
| Other | 12 | 13% |
| Unknown | 22 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 22 | 24% |
| Biochemistry, Genetics and Molecular Biology | 17 | 18% |
| Medicine and Dentistry | 12 | 13% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
| Neuroscience | 5 | 5% |
| Other | 6 | 7% |
| Unknown | 24 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 January 2014.
All research outputs
#4,319,668
of 25,220,525 outputs
Outputs from BMC Cancer
#1,049
of 8,904 outputs
Outputs of similar age
#34,023
of 203,395 outputs
Outputs of similar age from BMC Cancer
#11
of 105 outputs
Altmetric has tracked 25,220,525 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,904 research outputs from this source. They receive a mean Attention Score of 4.6. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 203,395 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 105 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 90% of its contemporaries.